CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.

[1]  B. Dörken,et al.  CD52 Is Not a Promising Immunotherapy Target for Most Patients with Multiple Myeloma , 2005, International Journal of Hematology.

[2]  C. Carlo-Stella,et al.  Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. , 2005, Experimental hematology.

[3]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[4]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Döhner,et al.  CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. , 2005, Haematologica.

[6]  D. Carrasco,et al.  Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. , 2004, Blood.

[7]  J. Teruya-Feldstein,et al.  Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. , 2004, Blood.

[8]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[9]  David M. Goldenberg,et al.  CD74 Is Expressed by Multiple Myeloma and Is a Promising Target for Therapy , 2004, Clinical Cancer Research.

[10]  Lisa L. Smith,et al.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. , 2004, Blood.

[11]  P. Workman,et al.  UKCCCR guidelines for the welfare of animals in experimental neoplasia. , 1988, British Journal of Cancer.

[12]  B. Barlogie,et al.  Treatment of multiple myeloma. , 2004, Blood.

[13]  Shaji K. Kumar,et al.  Expression of CD52 on plasma cells in plasma cell proliferative disorders. , 2003, Blood.

[14]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[15]  B. Coiffier.  Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma. , 2003, Blood reviews.

[16]  R. Mercier,et al.  Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Kimby,et al.  Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). , 2002, Blood.

[18]  J. Byrd,et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.

[19]  B. Leber,et al.  Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[21]  P. Croucher,et al.  In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells. , 2001, Experimental hematology.

[22]  G. Pruneri,et al.  Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. , 2000, Blood.

[23]  M. Dyer,et al.  Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Huhn,et al.  Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen , 1997, British journal of haematology.

[25]  M. Ferguson,et al.  Primary Structure of CD52 (*) , 1995, The Journal of Biological Chemistry.

[26]  T. Dexter,et al.  Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. , 1993, Blood.

[27]  G. Hale,et al.  The CAMPATH-1 antigen (CDw52). , 1990, Tissue antigens.

[28]  G. Hale,et al.  Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. , 1983, Blood.